These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27787387)

  • 1. Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial.
    Li FF; Jiang LL; Yan RN; Zhu HH; Zhou PH; Zhang DF; Su XF; Wu JD; Ye L; Ma JH
    Medicine (Baltimore); 2016 Oct; 95(43):e5229. PubMed ID: 27787387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
    Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
    Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R
    Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study.
    Elkind-Hirsch KE; Paterson MS; Seidemann EL; Gutowski HC
    Fertil Steril; 2017 Jan; 107(1):253-260.e1. PubMed ID: 28228317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia.
    Mintz ML; Minervini G
    Curr Med Res Opin; 2014 May; 30(5):761-70. PubMed ID: 24397584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes.
    Li FF; Liu BL; Yin GP; Yan RN; Zhang DF; Wu JD; Ye L; Su XF; Ma JH
    Sci Rep; 2018 Jun; 8(1):9713. PubMed ID: 29946148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
    Wan H; Zhao D; Shen J; Lu L; Zhang T; Chen Z
    J Diabetes Res; 2016; 2016():9849328. PubMed ID: 26798658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.
    Jain R
    Adv Ther; 2015 Nov; 32(11):1065-84. PubMed ID: 26578430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of baseline characteristics on glycemic effects of add-on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus.
    Fang H; Xu F; Du J; Liang L; Li W; Shen L; Wang X; Xu C; Bian F; Mu Y
    J Diabetes Investig; 2020 Jul; 11(4):896-905. PubMed ID: 32020731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial.
    Dore FJ; Domingues CC; Ahmadi N; Kundu N; Kropotova Y; Houston S; Rouphael C; Mammadova A; Witkin L; Khiyami A; Amdur RL; Sen S
    Cardiovasc Diabetol; 2018 May; 17(1):65. PubMed ID: 29724198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension.
    Kadowaki T; Muto S; Ouchi Y; Shimazaki R; Seino Y
    Expert Opin Pharmacother; 2017 Dec; 18(18):1903-1919. PubMed ID: 28901796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: predictive factors of the treatment response in type 2 diabetes.
    Gautier JF; Sauvanet JP
    Ann Endocrinol (Paris); 2011 Sep; 72(4):287-295. PubMed ID: 21777901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study.
    Hermans MP; Delibasi T; Farmer I; Lohm L; Maheux P; Piatti P; Malvolti E; Jörgens S; Charbonnel B
    Curr Med Res Opin; 2012 Oct; 28(10):1635-45. PubMed ID: 23020253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial.
    Jiang LL; Zhang P; Liu BL; Yan RN; Ye L; Ma JH; Li FF
    Biomed Res Int; 2021; 2021():6618257. PubMed ID: 34497852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin.
    Stenlöf K; Raz I; Neutel J; Ravichandran S; Berglind N; Chen R
    Curr Med Res Opin; 2010 Oct; 26(10):2355-63. PubMed ID: 20804445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous Glucose Monitoring in Newly Diagnosed Type 2 Diabetes Patients Reveals a Potential Risk of Hypoglycemia in Older Men.
    Li FF; Liu BL; Zhu HH; Li T; Zhang WL; Su XF; Wu JD; Wang XQ; Xu N; Yu WN; Yuan Q; Qi GC; Ye L; Lee KO; Ma JH
    J Diabetes Res; 2017; 2017():2740372. PubMed ID: 28271075
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment.
    Tao T; Wu P; Wang Y; Liu W
    BMC Endocr Disord; 2018 Feb; 18(1):14. PubMed ID: 29482528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks.
    Chacra AR; Tan GH; Ravichandran S; List J; Chen R;
    Diab Vasc Dis Res; 2011 Apr; 8(2):150-9. PubMed ID: 21562067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial.
    Leiter LA; Teoh H; Braunwald E; Mosenzon O; Cahn A; Kumar KM; Smahelova A; Hirshberg B; Stahre C; Frederich R; Bonnici F; Scirica BM; Bhatt DL; Raz I;
    Diabetes Care; 2015 Jun; 38(6):1145-53. PubMed ID: 25758769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of glycemic variation in diabetic patients receiving parenteral nutrition by continuous subcutaneous insulin infusion (CSII) therapy.
    Li FF; Zhang WL; Liu BL; Zhang DF; Chen W; Yuan L; Chen MY; Zhai XF; Wu JD; Su XF; Ye L; Cao HY; Ma JH
    Sci Rep; 2018 Apr; 8(1):5888. PubMed ID: 29651052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.